Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Determine MTD and to Evaluate PK, Safety/Tolerability and Efficacy Profiles of Antroquinonol (Hocena®) in NSCLC Patients Refractory to Conventional Treatment Modalities

NCT01134016 is registered in ClinicalTrials.gov with Golden Biotechnology Corporation as lead sponsor.

NCT NCT01134016
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01134016 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Determine MTD and to Evaluate PK, Safety/Tolerability and Efficacy Profiles of Antroquinonol (Hocena®) in NSCLC Patients Refractory to Conventional Treatment Modalities
Lead sponsor
Golden Biotechnology Corporation
Phase
Phase 1
Overall status
Completed
Start date
December 31, 2010
Completion date
June 30, 2013
Enrollment
13 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer